Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients

World Journal of Gastroenterology

Volumn 11, Issue 36, 2005, Pages 5735-5738

  Zhao, Po ^a   Liu, Wu ^a   Lu, Ya Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

FHIT; Gastric cancer; Gene expression; Prognosis

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; TISSUE DISTRIBUTION;

EID: 28044457713     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i36.5735     Document Type: Article

References (36)

1. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618-1624
2. Huebner K, Druck T, Siprashvili Z, Croce CM, Kovatich A, McCue PA. The role of deletions at the FRA3B/FHIT locus in carcinogenesis. Recent Results Cancer Res 1998; 154: 200-215
3. Druck T, Berk L, Huebner K. FHITness and cancer. Oncol Res 1998; 10: 341-345
4. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997; 57: 2256-2267
5. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, Goldstraw P, Huebner K, Croce CM, Pierotti MA. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57: 5207-5212
6. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56: 3173-3179
7. Bieche I, Latil A, Becette V, Lidereau R. Study of FHIT transcripts in normal and malignant breast tissue. Genes Chromosomes Cancer 1998; 23: 292-299
8. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999; 59: 3866-3869
9. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996; 93: 9770-9775
10. Zou TT, Lei J, Shi YQ, Yin J, Wang S, Souza RF, Kong D, Shimada Y, Smolinski KN, Greenwald BD, Abraham JM, Harpaz N, Meltzer SJ. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). Oncogene 1997; 15: 101-105
11. Michael D, Beer DG, Wilke CW, Miller DE, Glover TW. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 1997; 15: 1653-1659
12. Menin C, Santacatterina M, Zambon A, Montagna M, Parenti A, Ruol A, D'Andrea E. Anomalous transcripts and allelic deletions of the FHIT gene in human esophageal cancer. Cancer Genet Cytogenet 2000; 119: 56-61
13. Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate R. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosomes Cancer 1997; 20: 98-102
14. Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, Santoro E, Croce CM, Huebner K. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998; 58: 4708-4714
15. Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG, Cho MH. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 2001; 284: 850-855
16. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3; 8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-597
17. Zhao P, Lu Y, Hu Y, Zhong M, Li Z, Li X. Loss of fragile histidine triad expression in colorectal carcinoma. Zhonghua Binglixue Zazhi 2002; 31: 124-127
18. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP. Loss of fragile histidine triad epression in colorectal carcinomas and premalignant lesions. Cancer Res 2000; 60: 18-21
19. Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K, Scarpa A. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 1999; 59: 1308-1314
20. Hadaczek P, Siprashvili Z, Markiewski M, Domagala W, Druck T, McCue PA, Pekarsky Y, Ohta M, Huebner K, Lubinski J. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 1998; 58: 2946-2951
21. Werner NS, Siprashvili Z, Fong LY, Marquitan G, Schroder JK, Bardenheuer W, Seeber S, Huebner K, Schutte J, Opalka B. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res 2000; 60: 2780-2785
22. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, Mok JE, Munoz N, Bosch FX, Shah K, Cho KR. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997; 57: 4692-4698
23. Yoshino K, Enomoto T, Nakamura T, Nakashima R, Wada H, Saitoh J, Noda K, Murata Y. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer 1998; 76: 176-181
24. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999; 59: 5270-5274
25. Wu R, Connolly DC, Dunn RL, Cho KR. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst 2000; 92: 338-344
26. Chen YJ, Chen PH, Chang JG. Aberrant FHIT transcripts in hepatocellular carcinomas. Br J Cancer 1998; 77: 417-420
27. Schlott T, Ahrens K, Ruschenburg I, Reimer S, Hartmann H, Droese M. Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia. Br J Cancer 1999; 80: 73-78
28. Keck CL, Zimonjic DB, Yuan BZ, Thorgeirsson SS, Popescu NC. Nonrandom breakpoints of unbalanced chromosome translocations in human hepatocellular carcinoma cell lines. Cancer Genet Cytogenet 1999; 111: 37-44
29. Gramantieri L, Chieco P, Di Tomaso M, Masi L, Piscaglia F, Brillanti S, Gaiani S, Valgimigli M, Mazziotti A, Bolondi L. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis. Clin Cancer Res 1999; 5: 3468-3475
30. Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res 2000; 60: 1049-1053
31. Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA, Harris CC. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998; 58: 2533-2536
32. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032-5037
33. Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Rosler A, Blackburn GM, Siprashvili Z, Croce CM, Huebner K, Brenner C. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci USA 1998; 95: 5484-5489
34. Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K, McCue PA. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 2000; 88: 24-34
35. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003; 200: 39-46
36. Rocco A, Schandl L, Chen J, Wang H, Tulassay Z, McNamara D, Malfertheiner P, Ebert MP. Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 2003; 129: 84-88